Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 7, July, p. 861–869

doi: 10.17219/acem/93849

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Significance of apoptosis and autophagy of leukemic blasts for the outcomes of acute myeloid leukemia patients

Izabela Elżbieta Dereń-Wagemann1,A,B,C,D, Kazimierz Kuliczkowski1,A,C,E,F

1 Department of Hematology, Blood Cancers and Bone Marrow Transplantation, University Hospital No. 1, Wrocław, Poland

Abstract

Background. Cytostatic treatment induces apoptosis or other types of cell death like autophagy, necrosis, mitotic catastrophe, etc. Autophagy can play a role in the drug resistance of neoplastic cells, allowing the survival of blast cells under stressful conditions, such as the use of cytostatics. Studies on apoptosis and autophagy 12–24 h after the start of treatment have not been conducted until now.
Objectives. The study aimed to investigate the predictive and prognostic significance of autophagy and apoptosis in patients with acute myeloid leukemia (AML).
Material and Methods. The study included 38 patients. Blood was collected before and 12–24 h after the start of treatment, since at that time point, the appropriate blast cell count was still available. Autophagy was measured with the expression of the ATG5, MAP1L3, LC3-I, and LC3-II proteins. The percentage of mononuclear cells in early and late apoptosis was evaluated with flow cytometry, using the annexin V and propidium iodide (PI) binding assay.
Results. The percentage of apoptotic blast cells before treatment was not associated with the response. However, in the remission group, the overall percentage of apoptotic cells measured 12–24 h after the start of treatment was higher than in non-remission patients, which was statistically significant. In neither group we found any difference in the level of autophagy before and 12–24 h after the start of treatment. Nevertheless, we observed an increasing tendency of the MAP1LC3 protein expression (not statistically significant) in the remission group 12–24 h after the start of treatment. Patients with a higher percentage of blast cells in apoptosis and with a higher expression of MAP1LC3 protein measured 12–24 h after the start of the therapy had longer overall survival (OS).
Conclusion. A higher percentage of apoptotic as well as autophagic blast cells measured 12–24 h after the start of the chemotherapy is an independent factor associated with better outcomes.

Key words

apoptosis, acute myeloid leukemia, autophagy

References (25)

  1. Stępień A, Izdebska M, Grzanka A. Rodzaje śmierci komórki. Postepy Hig Med Dosw. 2007;61:420–428.
  2. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001;4(5):303–313.
  3. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extra­cellular cytokeratin 18. Cancer Res. 2004;64(5):1751–1756.
  4. Eom YW, Kim MA, Park SS, et al. Two distinct modes of cell death induced by doxorubicin: Apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene. 2005;24(30):4765–4777.
  5. Bellany CO, Malcomson RD, Harrisin DJ, Wyllie AH. Cell death in health and disease: The biology and regulation of apoptosis. Semin Cancer Biol. 1995;6(1):3–16.
  6. Yajima N, Sakamaki K, Yonehara S: Age‐related thymic involution is mediated by Fas on thymic epithelial cells. Int Immunol. 2004 Jul;16(7):1027–1035.
  7. Wyllie A. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metastasis Rev. 1992;11(2):95–103.
  8. Barni S, Pontiggia P, Bertone V, et al. Hyperthermia-induced cell death by apoptosis in myeloma cells. Biomed Pharmacother. 2001;55(3):170–173.
  9. Di Pietro R, Secchiero P, Rana R, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood. 2001;97(9):2596–2603.
  10. Nakao K, Otsuki Y, Akao Y, et al. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc. 2000;33(1):44–50.
  11. Bosnjak M, Ristic B, Arsikin K, et al. Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death. PLoS One. 2014;8:9(4):e94374.
  12. Han W, Sun J, Feng L, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One. 2011;6(12):e28491.
  13. Palmeira dos Santos C, Pereira GJ, Barbosa CM, Jurkiewicz A, Smaili SS, Bincoletto C. Comparative study of autophagy inhibition by 3MA and CQ on cytarabine-induced death of leukaemia cells. J Cancer Res Clin Oncol. 2014;140(6):909–920.
  14. Yang X, Lin J, Gong Y, et al. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol. 2012;30(3):123–130.
  15. Willems L, Chapuis N, Puissant A, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012;26(6):1195–1202.
  16. Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal. 2011;14(1):2201–2214.
  17. Glick D, Barth S, Macleod KF. Autophagy: Cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12.
  18. Klionsky DJ. Autophagy: From phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8(11):931–937.
  19. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328–341.
  20. Wysokińska E, Kałas W. Metody badania autofagii oparte na przemianach białek MAP1LC3 i p62/SQSTM1. Postepy Hig Med Dosw. 2013;67:442–448.
  21. Smith BD, Bambach BJ, Vala MS, et al. Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br J Haematol. 1998;102(4):1042–1049.
  22. Martinez-Lorenzo MJ, Gamen S, Etxeberria J, et al. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells. Int J Cancer. 1998;75(3):473–481.
  23. Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome inacute myeloid leukemia patients. Leuk Res. 2010;34(10):1308–1313.
  24. Oliver L, Vavasseur F, Mahé B, et al. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia. Br J Haematol. 2002;118(2):434–437.
  25. Belaud-Rotureau MA, Durrieu F, Labroille G, et al. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia. 2000;14(7):1266–1275.
© Wroclaw Medical University